Durham dermatology firm submits gel targeting ‘viral skin infection’ to FDA

DURHAM – Novan, a medical dermatology firm, has submitted a new drug application to the FDA and hopes to win approval for it in early 2024.

The topical gel targets molluscum contagiosum, which affects some 6 million people in the U.S.

For more details, read the full announcement at:

https://www.globenewswire.com/news-release/2023/01/06/2584394/0/en/Novan-Submits-New-Drug-Application-to-the-U-S-FDA-for-Berdazimer-Gel-10-3-SB206-for-the-Treatment-of-Molluscum-Contagiosum.html